

## Disclosures

### Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Aidoc	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Noninvasive Imaging</a>
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Arrowhead	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Ionis	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Prevention</a>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Prevention</a>
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Prevention</a>
Tourmaline Bio	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Prevention</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Society of Preventive Cardiology	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<a href="#">Prevention</a>

### Clinical Trial Enroller (14)

Trial Name	Trial Sponsor	Trial Funding Source
OCEAN(a)	Amgen Inc.	
TRANSFORM	Cleerly	
ACCLAIM	Eli Lilly and Company	
CLEAR-PATH	Esperion	
CORE Study	Ionis	
MK-0616-015 and-017 Studies	Merck & Co., Inc.	
PREVENTABLE	National Institutes of Health	
BROOKLYN	New Amsterdam	
PREVAIL	New Amsterdam	
Victorion INCLUSION	Novartis	
FRONTIER CAVS	Novartis Corporation	
Victorion 2-PREVENT	Novartis Corporation	
Victorion 1-PREVENT	Novartis Corporation	
ORION-16	Novartis Corporation	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

# Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 7/19/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 7/19/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 7/19/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 7/18/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.